Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Utilities Select Sector SPDR Fund — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.69 (market cap $8.04B), while Utilities Select Sector SPDR Fund trades at $45.7. The key difference: Utilities Select Sector SPDR Fund is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | XLU | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | — |
52-Week High | $339.75 | $47.73 |
52-Week Low | $241.71 | $40.99 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
XLU trades at $45.72, up 0.68% today, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. The ETF benefits from growing electricity demand driven by AI data centers and clean energy transitions, positioning utilities as both defensive and growth-oriented investments. Recent news highlights XLU's role in powering AI infrastructure, with top holdings securing long-term power agreements with major tech firms.
Outlook remains positive due to structural power demand growth, though risks include regulatory changes and grid capacity constraints. Wall Street sentiment is bullish with strong institutional interest, but investors should monitor interest rate sensitivity and execution of capital expenditure plans for new power generation assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
